ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0513

The Association Between Age of Diagnosis and Disease Characteristics and Damage in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Jessica Bloom1, Kaci Pickett2, Lori Silveira2, David Cuthbertson3, Nader Khalidi4, Curry Koening5, Carol Langford6, Carol McAlear7, Paul Monach8, Larry Moreland1, Christian Pagnoux9, Rennie Rhee10, Philip Seo11, Ulrich Specks12, Kenneth J. Warrington12, Robert Fuhlbrigge1 and Peter Merkel10, 1University of Colorado, Denver, CO, 2University of Colorado Anschutz Medical Campus, Aurora, CO, 3University of South Florida, Tampa, FL, 4McMaster University, Hamilton, ON, Canada, 5University of Texas Dell Medical School, Austin, TX, 6Cleveland Clinic, Cleveland, OH, 7University of Pennsylvania, Philadelphia, 8VA Boston Healthcare System, Boston, MA, 9Mount Sinai Hospital, Toronto, ON, Canada, 10University of Pennsylvania, Philadelphia, PA, 11Johns Hopkins University, Baltimore, MD, 12Mayo Clinic, Rochester, MN

Meeting: ACR Convergence 2022

Keywords: ANCA, ANCA associated vasculitis, Pediatric rheumatology, Vasculitis, Wegener's

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Abstracts: Pediatric Rheumatology – Clinical I: Connective Tissue Disease

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Clinical characteristics and outcomes often differ between children and adults diagnosed with the same rheumatic condition; however, such comparative data is limited in ANCA-associated vasculitis (AAV). The objective of this study was to examine the relationship between age of diagnosis and disease characteristics and damage outcomes in patients with AAV.

Methods: This was a retrospective cohort analysis of patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) enrolled in the Vasculitis Clinical Research Consortium Longitudinal Studies from 2013 to 2021. Cohorts were divided by age of diagnosis (years): children (< 18), young adults (18-40), middle-aged ( > 40-65), and older adults ( > 65). Outcomes included demographics, ANCA type, and clinical characteristics. Group differences were tested using the Kruskal-Wallis test for continuous variables and Fisher’s exact test for categorical. Univariate and multivariate linear regression were used to estimate the differences in damage scores, Vasculitis Damage Index [VDI] and ANCA Vasculitis Index of Damage [AVID].

Results: Data from 1020 patients were analyzed: 61 children, 240 young adults, 560 middle aged, and 159 older adults (Table 1). 852 (84%) had GPA and 165 (16%) had MPA. 893 (92%) of patients with ANCA results were ANCA positive: 637 (65%) with PR3-ANCA, 247 (25%) with MPO-ANCA, and 9 (1%) with both. AAV diagnosed in childhood had a female predominance that decreased with age and was more often GPA and ANCA/PR3-ANCA positive. Older adults had more MPA and MPO-ANCA. Those diagnosed in childhood experienced more subglottic stenosis and alveolar hemorrhage at diagnosis and ever. Ocular, nasal, sinus, renal, gastrointestinal, and nervous system manifestations were also different between groups. Over half of patients diagnosed in childhood received both cyclophosphamide (CYC) and rituximab (RTX) (Figure 1), a rate that decreased with increasing age groups. The percentage of patients receiving neither CYC or RTX, or CYC alone increased with older age at diagnosis. After adjusting for disease duration and use of CYC and/or RTX, the VDI and AVID scores of those diagnosed at age > 65 years were estimated to be 1.73 and 2.52 points higher, respectively, than those diagnosed as children (95%CI: [1.03,2.43], p < 0.001; [1.26,3.78], p < 0.001) (Table 2).

Conclusion: There is an association between age of diagnosis and clinical characteristics in patients with AAV, particularly when diagnosed in childhood. Most notably, children experience more subglottic stenosis and alveolar hemorrhage. An early-age female predominance wanes across age groups. Patients diagnosed in childhood are more likely to receive both CYC and RTX, a finding that may indicate different practices in pediatrics. Those diagnosed at an older age accrued more damage than those diagnosed at a younger age. While studies often exclude children, sub-analyses of adults diagnosed in childhood and more specific damage scores could provide insight into the unique aspects of AAV across the lifespan, allowing for more evidence-based care and improved outcomes.

Supporting image 1

Supporting image 2

Figure 1. Medications ever received by patients with granulomatosis with polyangiitis and microscopic polyangiitis stratified by age at diagnosis

Supporting image 3


Disclosures: J. Bloom, None; K. Pickett, None; L. Silveira, None; D. Cuthbertson, None; N. Khalidi, AstraZeneca, Bristol-Myers Squibb(BMS), GlaxoSmithKlein(GSK), Roche, Sanofi, AbbVie/Abbott, Katsaka Medical, Otsuka; C. Koening, chemocentryx; C. Langford, None; C. McAlear, None; P. Monach, Chemocentryx, Kiniksa, BMS/Celgene, Gilead; L. Moreland, None; C. Pagnoux, otsuka, AstraZeneca, pfizer; R. Rhee, ChemoCentryx; P. Seo, None; U. Specks, AstraZeneca, Bristol-Myers Squibb(BMS), GlaxoSmithKlein(GSK), Genentech, AstraZeneca, Boehringer-Ingelheim, ChemoCentryx; K. Warrington, Eli Lilly, GlaxoSmithKlein(GSK), Kiniksa, Chemocentryx; R. Fuhlbrigge, None; P. Merkel, AbbVie, AstraZeneca, Boeringher-Ingelheim, Bristol-Myers Squibb, ChemoCentryx, Forbius, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Neutrolis, Takeda, CSL Behring, Dynacure, EMDSerono, Immagene, Jannsen, Kiniksa, Magenta, Novartis, Pfizer, Q32, Regeneron, Sparrow, Eicos, Electra, Kyverna, UpToDate.

To cite this abstract in AMA style:

Bloom J, Pickett K, Silveira L, Cuthbertson D, Khalidi N, Koening C, Langford C, McAlear C, Monach P, Moreland L, Pagnoux C, Rhee R, Seo P, Specks U, Warrington K, Fuhlbrigge R, Merkel P. The Association Between Age of Diagnosis and Disease Characteristics and Damage in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-association-between-age-of-diagnosis-and-disease-characteristics-and-damage-in-patients-with-antineutrophil-cytoplasmic-antibody-associated-vasculitis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-association-between-age-of-diagnosis-and-disease-characteristics-and-damage-in-patients-with-antineutrophil-cytoplasmic-antibody-associated-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology